In a related
editorial comment, Paolo Boffetta, M.D., M.P.H., associate director for population sciences at The Tisch Cancer Institute and chief of the Division of Cancer Prevention and
Control of the at Mount Sinai in New York, addressed whether the increased risk of cancer in this group of heart failure patients warranted
additional screening beyond what was recommended for the general public.